Metformin ameliorates core deficits in a mouse model of fragile X syndrome.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28504725.
- Also identified by DOI 10.1038/nm.4335.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fragile X syndrome (FXS) is the leading monogenic cause of autism spectrum disorders (ASD). Trinucleotide repeat expansions in FMR1 abolish FMRP expression, leading to hyperactivation of ERK and mTOR signaling upstream of mRNA translation. Here we show that metformin, the most widely used drug for type 2 diabetes, rescues core phenotypes in Fmr1<sup>-/y</sup> mice and selectively normalizes ERK signaling, eIF4E phosphorylation and the expression of MMP-9. Thus, metformin is a potential FXS therapeutic.
Medical subject headings
- Behavior, Animal
- Eukaryotic Initiation Factor-4E
- Fragile X Messenger Ribonucleoprotein 1
- Fragile X Syndrome
- Hypoglycemic Agents
- MAP Kinase Signaling System
- Matrix Metalloproteinase 9
- Metformin
- Social Behavior